The fourth Forum, on acute myeloid leukemia (AML), resulted, for the first time, in two prioritization meetings—FLT3 inhibitors and CD123 antibodies; this produced a consensus of high-priority classes of compounds, based on available scientific evidence, and proposed a coordinated development with cooperative groups (11). The gene discussed is FLT3; the disease is acute myeloid leukemia.